Exelixis Corp - EXEL Quarterly EPS earnings growth

Corporate company logo of Exelixis (EXEL)

Ownership of patents for targeted oncology therapy allows Exelixis, Inc. (EXEL) to command premium pricing due to low demand elasticity. The growth rate of quarterly earnings per share reflects current dynamics, where the actual level is 22.80. Stability is driven by Cabometyx sales, while market positions are strengthened by a narrow specialization in treating complex solid tumors of the kidneys and liver.

exelixis.com (EXEL) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/14/2026

Analytical breakdowns for Exelixis, Inc.

- share price and consensus valuation forecast:
Stock Quotes Exelixis|EXEL - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Exelixis Corp|EXEL - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Exelixis|EXEL - Accounting Value of Company|Market Capitalization to Book Value Ratio exelixis.com|EXEL - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Exelixis, Inc.|EXEL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Exelixis, Inc.|EXEL - Company Cumulative Indebtedness|Debts to Book Capitalization Exelixis Corp|EXEL - Long-Term Debt|Company Short-Term Debts Exelixis|Quick Liquidity Indicator exelixis.com
- earnings and market multiples details:
EXEL - Final Profit|Future Profit Exelixis, Inc.|EXEL - Market Price to Net Income Ratio|Forward P/E Multiple Exelixis Corp|EXEL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Exelixis Corp|EXEL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Exelixis|EXEL - Earnings per share for the trailing year|Quarterly EPS earnings growth exelixis.com|EXEL - Earnings growth in current year|Net earnings per share growth forecast for next year Exelixis, Inc.
- sales revenue and business income indicators:
EXEL - Company Annual Revenue|Company Future Sales Volume Exelixis|EXEL - Price to Sales|Forward P/S Multiple Exelixis Corp
Fundamental company valuation:Exelixis - EXEL
Flagship merchandise of exelixis.com

This indicator measures the dynamics of net earnings per share by linking quarterly changes to daily market value. For Exelixis, Inc. (EXEL), the recorded quarterly EPS growth confirms the monetization of Cabozantinib patents within the targeted therapy segment. The narrowing volatility on this chart signals stabilizing revenues. However, excessive stagnation may mask an emerging negative trend. The indicator's steady trajectory verifies the fundamental strength of the business.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|NUVL: Year-over-year earnings per share growth rate for the last twelve months|KYMR (Kymera Therapeutics Inc) - Quarterly EPS earnings growth|Quarterly EPS earnings growth IDEAYA Corp|Year-over-year earnings per share growth for the last twelve months Enliven Therapeutics (ELVN)|ORIC (oricpharma.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics, Inc.)|Net earnings per share growth for the trailing year Nurix Therapeutics Inc|Tyra Bio - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (Immuneering) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Therapeutics Inc CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Bio Green Med Solution Inc. - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)